Skip to main content
GutCited

Omega-3 Fatty Acids (EPA/DHA) per Ulcerative Colitis (UC)

C

Mixed results in maintaining UC remission. Some meta-analyses show modest benefit; others show no significant effect. EPA may be more beneficial than DHA.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dulcerative\u002Dcolitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

In sintesi

Mixed results in maintaining UC remission. Some meta-analyses show modest benefit; others show no significant effect. EPA may be more beneficial than DHA.

Key Study Findings

Review
Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment.
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: patients with ulcerative colitis

Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None vs: None Outcome: Athletic performance and nutritional optimization Effetto: None None

Popolazione: Vegan athletes (narrative review)

Review
From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel …
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: None

Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None vs: None Outcome: IBD microbiota modulation and immune regulation Effetto: None None

Popolazione: IBD patients (review of nutritional interventions)

Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None vs: None Outcome: Colitis severity Effetto: None None

Popolazione: Crohn's disease patients

Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None vs: None Outcome: Diet-genetics interaction in IBD Effetto: None None

Popolazione: IBD patients (editorial commentary)

Key Statistics

8

Studi

1000

Partecipanti

Mixed

C

Grado

Referenced Papers

Gastroenterology clinics of … 2018 67 citazioni
Annals of gastroenterology 2016 80 citazioni
European journal of … 2016 79 citazioni
Clinics in dermatology 2016 19 citazioni
World journal of … 2014 25 citazioni
Alimentary pharmacology & … 2013 128 citazioni
The British journal … 2012 145 citazioni
The Cochrane database … 2012 130 citazioni
JRSM short reports 2010 11 citazioni
The Cochrane database … 2007 118 citazioni
Journal of the … 2002 2016 citazioni
Drugs 1998 99 citazioni
Bailliere's clinical gastroenterology 1997 26 citazioni
The American journal … 1991 2278 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
1,000-2,000 mg combined EPA/DHA per day
ibdsupport:
2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)

Limite massimo: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Mixed --
None -- Positive --
None -- Mixed --
None -- Positive --
None -- Neutral --
None -- Neutral --
95% -- Mixed 124
95% -- Mixed --

Momento migliore per l'assunzione: With meals containing fat for better absorption

Safety & Side Effects

Effetti collaterali segnalati

  • Fishy aftertaste and burping
  • Mild gastrointestinal discomfort (nausea, diarrhea)
  • Potential increased bleeding time at very high doses (>3 g/day)
  • May lower blood pressure slightly

Interazioni note

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)
  • Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)

Livello di assunzione massimo tollerabile: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Omega-3 Fatty Acids (EPA/DHA) help with Ulcerative Colitis (UC)?
Based on 8 studies with 1,000 participants, there is limited but promising evidence that Omega-3 Fatty Acids (EPA/DHA) may support Ulcerative Colitis (UC) management. Our evidence grade is C (Some Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Ulcerative Colitis (UC)?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Ulcerative Colitis (UC)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 8 peer-reviewed studies with 1,000 total participants. The overall direction of effect is mixed.

Related Evidence

Omega-3 Fatty Acids (EPA/DHA) per altre condizioni

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.